Development and validation of mPCR-CEFA for detecting multiple deletion and non-deletion thalassemia genotypes

开发和验证用于检测多种缺失和非缺失型地中海贫血基因型的mPCR-CEFA

阅读:1

Abstract

BACKGROUND: Thalassemia is a common hereditary blood disorder caused by genetic variants in globin genes, leading to abnormal hemoglobin production. Rapid and accurate genotyping is essential for molecular screening and prenatal genetic diagnosis to prevent the birth of individuals with severe forms of the disease. METHODS: We developed a multiplex PCR-capillary electrophoresis fragment analysis (mPCR-CEFA) method to detect 16 α-thalassemia and 24 β-thalassemia genotypes simultaneously. Genomic DNA extracted from clinical blood samples underwent a two-tube multiplex PCR amplification. The amplification products were analyzed using capillary electrophoresis to detect mutation peaks in different fluorescent channels and to calculate α1/α2 and Y1/Y2 ratios for genotype determination. The performance of mPCR-CEFA was validated against conventional methods, including Gap-PCR and PCR-RDB. RESULTS: The α1/α2 and Y1/Y2 peak ratios exhibited stable and reproducible values, allowing for precise genotyping of thalassemia events involving homologous recombination, such as -α(3.7), -α(4.2), ααα(anti3.7), ααα(anti4.2) and HKαα. Mutation peaks in different fluorescent channels also facilitated the differentiation of various genotypes, including deletion and non-deletion types. The method demonstrated a high accuracy rate of 99.5%. It successfully detected complex compound genotypes like α(CD 74)α/-α(4.2), β(CD 17)/β(N) and α(WS)α/--(SEA), β(CD 37)/β(N) (or α(WS)α/--(SEA), β(CD 37)/β(CD 37)), which were challenging for traditional approaches. CONCLUSION: The mPCR-CEFA method is a reliable, efficient, and scalable tool for genetic diagnosis of thalassemia. Its ability to detect multiple genotypes simultaneously and resolve complex cases makes it particularly valuable for large-scale screening and clinical applications. This approach holds significant potential for improving thalassemia prevention strategies and supporting public health efforts in high-prevalence regions.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。